214 related articles for article (PubMed ID: 32020284)
21. A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice.
Liu X; Da Z; Wang Y; Niu H; Li R; Yu H; He S; Guo M; Wang Y; Luo Y; Ma X; Zhu B
Vaccine; 2016 Mar; 34(11):1370-8. PubMed ID: 26845736
[TBL] [Abstract][Full Text] [Related]
22. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.
Luabeya AK; Kagina BM; Tameris MD; Geldenhuys H; Hoff ST; Shi Z; Kromann I; Hatherill M; Mahomed H; Hanekom WA; Andersen P; Scriba TJ; ; Schoeman E; Krohn C; Day CL; Africa H; Makhethe L; Smit E; Brown Y; Suliman S; Hughes EJ; Bang P; Snowden MA; McClain B; Hussey GD
Vaccine; 2015 Aug; 33(33):4130-40. PubMed ID: 26095509
[TBL] [Abstract][Full Text] [Related]
23. The Mincle-activating adjuvant TDB induces MyD88-dependent Th1 and Th17 responses through IL-1R signaling.
Desel C; Werninghaus K; Ritter M; Jozefowski K; Wenzel J; Russkamp N; Schleicher U; Christensen D; Wirtz S; Kirschning C; Agger EM; Prazeres da Costa C; Lang R
PLoS One; 2013; 8(1):e53531. PubMed ID: 23308247
[TBL] [Abstract][Full Text] [Related]
24. T Cells Primed by Live Mycobacteria Versus a Tuberculosis Subunit Vaccine Exhibit Distinct Functional Properties.
Lindenstrøm T; Moguche A; Damborg M; Agger EM; Urdahl K; Andersen P
EBioMedicine; 2018 Jan; 27():27-39. PubMed ID: 29249639
[TBL] [Abstract][Full Text] [Related]
25. CpG7909 adjuvant enhanced immunogenicity efficacy in mice immunized with ESAT6-Ag85A fusion protein, but does not confer significant protection against Mycobacterium tuberculosis infection.
Hu S; Chen H; Ma J; Chen Q; Deng H; Gong F; Huang H; Shi C
J Appl Microbiol; 2013 Nov; 115(5):1203-11. PubMed ID: 23902541
[TBL] [Abstract][Full Text] [Related]
26. Peptide-specific T helper cells identified by MHC class II tetramers differentiate into several subtypes upon immunization with CAF01 adjuvanted H56 tuberculosis vaccine formulation.
Prota G; Christensen D; Andersen P; Medaglini D; Ciabattini A
Vaccine; 2015 Nov; 33(48):6823-30. PubMed ID: 26494626
[TBL] [Abstract][Full Text] [Related]
27. Design of Gadoteridol-Loaded Cationic Liposomal Adjuvant CAF01 for MRI of Lung Deposition of Intrapulmonary Administered Particles.
Thakur A; Rose F; Ansari SR; Koch P; Martini V; Ovesen SL; Quistorff B; Maritim S; Hyder F; Andersen P; Christensen D; Mori Y; Foged C
Mol Pharm; 2019 Nov; 16(11):4725-4737. PubMed ID: 31539263
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and protective efficacy of novel Mycobacterium tuberculosis antigens.
Derrick SC; Yabe IM; Yang A; Kolibab K; Hollingsworth B; Kurtz SL; Morris S
Vaccine; 2013 Sep; 31(41):4641-6. PubMed ID: 23906890
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant Potential of Poly-α-l-Glutamine from the Cell Wall of Mycobacterium tuberculosis.
Mani R; Gupta M; Malik A; Tandon R; Prasad R; Bhatnagar R; Banerjee N
Infect Immun; 2018 Oct; 86(10):. PubMed ID: 30104212
[TBL] [Abstract][Full Text] [Related]
30. Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice.
Todoroff J; Lemaire MM; Fillee C; Jurion F; Renauld JC; Huygen K; Vanbever R
PLoS One; 2013; 8(5):e63344. PubMed ID: 23675482
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Vaccination with Cationic Liposomes Formulated with Dioctadecyldimethylammonium and Trehalose Dibehenate (CAF01) and Peptide P10 Is Protective in Mice Infected with
Araújo MV; Santos Júnior SRD; Nosanchuk JD; Taborda CP
J Fungi (Basel); 2020 Dec; 6(4):. PubMed ID: 33302372
[TBL] [Abstract][Full Text] [Related]
32. Liposome-based cationic adjuvant formulations (CAF): past, present, and future.
Christensen D; Agger EM; Andreasen LV; Kirby D; Andersen P; Perrie Y
J Liposome Res; 2009; 19(1):2-11. PubMed ID: 19515003
[TBL] [Abstract][Full Text] [Related]
33. Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants.
Hussain MJ; Wilkinson A; Bramwell VW; Christensen D; Perrie Y
J Pharm Pharmacol; 2014 Mar; 66(3):358-66. PubMed ID: 24251796
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-23 instructs protective multifunctional CD4 T cell responses after immunization with the Mycobacterium tuberculosis subunit vaccine H1 DDA/TDB independently of interleukin-17A.
Ritter K; Behrends J; Erdmann H; Rousseau J; Hölscher A; Volz J; Prinz I; Lindenstrøm T; Hölscher C
J Mol Med (Berl); 2021 Nov; 99(11):1585-1602. PubMed ID: 34351501
[TBL] [Abstract][Full Text] [Related]
35. Adsorption of protein antigen to the cationic liposome adjuvant CAF®01 is required for induction of Th1 and Th17 responses but not for antibody induction.
Wørzner K; Hvannastein J; Schmidt ST; Foged C; Rosenkrands I; Pedersen GK; Christensen D
Eur J Pharm Biopharm; 2021 Aug; 165():293-305. PubMed ID: 34044110
[TBL] [Abstract][Full Text] [Related]
36. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human.
van Dissel JT; Joosten SA; Hoff ST; Soonawala D; Prins C; Hokey DA; O'Dee DM; Graves A; Thierry-Carstensen B; Andreasen LV; Ruhwald M; de Visser AW; Agger EM; Ottenhoff TH; Kromann I; Andersen P
Vaccine; 2014 Dec; 32(52):7098-107. PubMed ID: 25454872
[TBL] [Abstract][Full Text] [Related]
37. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements.
Agger EM; Rosenkrands I; Hansen J; Brahimi K; Vandahl BS; Aagaard C; Werninghaus K; Kirschning C; Lang R; Christensen D; Theisen M; Follmann F; Andersen P
PLoS One; 2008 Sep; 3(9):e3116. PubMed ID: 18776936
[TBL] [Abstract][Full Text] [Related]
38. Immunocorrelates of CAF family adjuvants.
Pedersen GK; Andersen P; Christensen D
Semin Immunol; 2018 Oct; 39():4-13. PubMed ID: 30396811
[TBL] [Abstract][Full Text] [Related]
39. Subunit vaccine H56/CAF01 induces a population of circulating CD4 T cells that traffic into the Mycobacterium tuberculosis-infected lung.
Woodworth JS; Cohen SB; Moguche AO; Plumlee CR; Agger EM; Urdahl KB; Andersen P
Mucosal Immunol; 2017 Mar; 10(2):555-564. PubMed ID: 27554293
[TBL] [Abstract][Full Text] [Related]
40. Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation.
Werninghaus K; Babiak A; Gross O; Hölscher C; Dietrich H; Agger EM; Mages J; Mocsai A; Schoenen H; Finger K; Nimmerjahn F; Brown GD; Kirschning C; Heit A; Andersen P; Wagner H; Ruland J; Lang R
J Exp Med; 2009 Jan; 206(1):89-97. PubMed ID: 19139169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
